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Abstract 
Our understanding of the link between the human microbiome and disease, including obesity, 
inflammatory bowel disease, arthritis and autism, is rapidly expanding. Improvements in the 
throughput and accuracy of DNA sequencing of the genomes of microbial communities 
associated with human samples, complemented by analysis of transcriptomes, proteomes, 
metabolomes and immunomes, and mechanistic experiments in model systems, have vastly 
improved our ability to understand the structure and function of the microbiome in both diseased 
and healthy states. However, many challenges remain. In this Review, we focus on studies in 
humans to describe these challenges, and propose strategies that leverage existing knowledge to 
move rapidly from correlation to causation, and ultimately to translation.  
  
Introduction 
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The microbial cells that colonize the human body, including in mucosal and skin environments, 
are at least as abundant as our somatic cells1, and certainly contain far more genes than our 
human genome (Box 1).  An estimated 500-1000 species of bacteria exist in the human body at 
any one time2, although the number of unique genotypes (sub-species) could be orders of 
magnitude greater than this3. Each bacterial strain has a genome containing thousands of genes, 
offering substantially more genetic diversity and hence flexibility than the human genome. 
However, different people harbour radically different collections of microbes with substantially 
varying densities even among conserved taxa, and we understand little about what leads to and 
what regulates this variation. Importantly, we do not yet understand how the variation within a 
person over time, or between different people, influences wellness, the preservation of health, or 
the onset and progression of disease. However, we do know that changes in the microbiome, and 
microbial metabolome and their interaction with the immune, endocrine, and nervous system are 
correlated with a wide array of illnesses, ranging from inflammatory bowel disease 4–6 to cancer7 
to major depressive disorder 8,9.  
 
Human microbiome investigations have now reached a critical inflection point. We are 
transitioning from description and investigation to understanding mechanism, and developing 
novel clinical interventions based on this understanding10 . These advances have also created a 
surge in translational research, resulting in substantial private investment not only in academic 
research, but also in the private sector, including so-called “Big Pharma”. This drive toward 
clinical microbiome studies is supported by a revolution in personalized medicine, in which, for 
example, the decline in cost of cancer genome sequencing is allowing the rapid identification of 
the precise treatment regimen that will lead to a positive outcome in an individual patient, for 
example, with colorectal cancer11 . Our ability to rapidly and reproducibly characterize the 
microbiome, like cancer genomics, offers an opportunity to develop fundamentally new 
diagnostic biomarkers and therapeutics.  
 
Here we present the current state of knowledge linking the microbiome to human disease. We 
have focused on human studies when possible, but also highlight select mouse studies when 
  3 
human studies are not available. This is to provide a platform from which to explore the future of 
applied clinical microbiome research.  
 
We will strategize on how to progress from the correlative and biomarker studies towards studies 
that will reveal the underlying mechanisms and opportunities for new preventive and therapeutic 
modalities.  
 
Factors influencing the human microbiome 
 
To alter the microbiome deliberately for preventive or therapeutic purposes, or use it to 
understand a particular medical condition, we must first understand the factors that influence its 
composition. We have reviewed many of these factors in detail recently10,12, so we provide only 
a brief summary here. 
 
Human genetics and immune interactions in early development  
The composition of the human microbiome is unique in each individual, and the differences 
among individuals are large compared to the typical biochemical differences within a person 
over time13,14. Identical twins are barely more similar to one another in microbial composition 
and structure than are non-identical twins15, at least over the range of environmental factors 
captured in studies to date, suggesting that the effect of the human genome is limited, and that 
most of microbial community assembly may be determined by environmental factors. Early 
underpowered studies suggested that monozygotic twins were no more similar in terms of their 
overall gut microbiota than dizygotic twins16–18, although larger cohort sizes show a small but 
statistically significant effect of genetics on microbiome composition in twins with certain taxa 
being identified as highly heritable, such as Christensenella15. However, one way to rationalize 
this is that the number of bacteria that are able to successfully colonize humans is limited. 
Colonizing initially germ-free mice with diverse environmental samples demonstrates that very 
few bacteria present in the environment can survive in the mouse gut, and those that do are 
rapidly displaced by human- or mouse-derived bacteria on exposure19 Furthermore, human 
immune responses shape responses to changes in the microbiome and are involved in shaping the 
microbiome itself20.  
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Most human immunological studies regrettably still lack a microbiome component, that will be 
essential to untangling the relationship between the immune response and microbial colonisation 
and stability. The mammalian immune system has a complex and dynamic bidirectional 
relationship with the microbiome. Although, recent human cohort studies suggest that most of 
the variability in human immune response to stimulation derives from the genome, at least 10% 
of this immune response variability derives directly from interactions associated with the 
microbiome21.  
 
The large majority of microbiome colonization occurs in the early years of life. This topic has 
been reviewed extensively22,23. During and shortly after birth, newborns are exposed to maternal 
and environmental microbes initiating gut microbiome establishment24.  Within the first year of 
life, an estimated 1013 to 1014 microbes/ml comprising 500-1000 species colonize the 
gastrointestinal tract25. After weaning, the gut microbiota becomes firmly established, leading to 
a lifelong microbiome signature in healthy individuals26.  
  
Body site  
When  the microbiomes of large cohorts of people at a given body site are compared, individuals 
fit on a continuum of microbial diversity within a human population, rather than clustering into 
discrete groups27,28. During human development, the human microbiome follows body site-
specific trajectories, so that each body site develops a specific biogeography (Figure 1). The 
skin, for example, shows dramatic variation in microbiome composition and structure across 
different sites29. The physical and topographical characteristics of skin play a significant role in 
shaping the microbial community similarity between sites30. These factors also play a role in 
shaping the individuality of the microbiome, so that each person develops a unique microbial 
signature on their skin, irrespective of the differences between skin sites31. Similarly, although 
prolonged physical oral interaction between humans influences microbial community 
composition over time32, the oral microbiome still maintains a relatively unique composition in 
each person33. Longitudinal characterization of the human gut microbiome has shown that the 
adult microbiota remain relatively stable and unique to each person, compared to the drastic 
change over the first three years of life31,34.  
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However, the microbiome is a living ecosystem, and consequently undergoes fluctuations in the 
growth rate and survival of each of its constituents. For example, changes in diet can profoundly 
impact the gut microbial community structure35,36, and vigorous cleaning can temporarily alter 
the skin microbiome. However, in both cases the original microbiota and structure re-emerge 
when the original conditions resume37. Transit time of food through the gut  also influences the 
types of microbes which can proliferate within the gut, with rapid transit time selecting for 
functions associated with biofilm formation or rapid cell division38,39 . Defining a microbiota 
based on the relative abundance of its members may therefore provide only a limited view of the 
microbial assemblage, and integrating more information about the function of each gene and 
genome in the context of the ecosystem and the host will provide increasingly important insights. 
Human microbiome variability makes blanket stratification difficult for particular disease states, 
although it is possible to identify biomarkers for some conditions [Box 2].  
 
The vaginal microbiome has a similar degree of stability to the skin microbiome, and unlike the 
gut, classifying the vaginal microbiome into discrete states during disease has been possible. The 
vaginal microbiota of asymptomatic women tend to be dominated by individual species of 
Lactobacillus and diverse additional anaerobic taxa40. The Lactobacilli are believed to benefit the 
host by lowering vaginal pH through fermentation end-products, thereby reducing the likelihood 
of allochthonous microbial colonization or pathogen invasion. Microbial variation within an 
individual woman does occur over days to weeks41, although menstruation and pregnancy appear 
to result in a similar microbiome in different groups of women42. Diseases such as bacterial 
vaginosis result in disruption of the ‘normal’ vaginal ecosystem function, but also result in a 
highly similar microbial profile between women, thereby providing a generalized biomarker of 
disease43. 
 
Diet 
Diet has been studied extensively in relation to the gut microbiome44, but less so with respect to 
other microbiomes at other sites across the body. Modulating diet is an ideal opportunity for low-
risk, culturally and psychologically acceptable intervention to change the microbiome. 
Therefore, this avenue of research could yield novel therapeutic strategies through targeted 
  6 
dietary interventions should gut microbiota be shown to be causative for certain diseases. 
Evidence to date suggests that long-term diet has very large effects on gut microbiome 
composition45 although a sufficiently extreme short-term dietary change can cause people to 
resemble one another within days35. Fascinatingly, the effects of the same dietary ingredient on 
blood glucose measurements can vary in different people, an effect mediated by the 
microbiome46. Although we know that the microbiome can influence leptin concentrations in 
humans, and hence influence appetite47, an open question is whether the microbiome can 
influence dietary preferences, which could lead to positive feedback loops when these dietary 
changes in turn alter the microbiome. 
 
Antibiotics 
The effect of antibiotics on all microbiomes is expected to be large compared to other factors, 
and preliminary studies have been performed to determine the impact48. The gut microbiome in 
adults appears not to be resilient to repeated antibiotic administration49. The same antibiotic 
appears to affect particular microbes differently depending on the rest of the microbiome50, 
perhaps due to different growth phases, metabolic states, or contextual microbial network in 
which the microorganisms find themselves. An especially interesting area of research is the 
increasing evidence that antibiotics in early life have a profound effect of the gut microbiome 
that can result in the later development of obesity51, asthma, inflammatory bowel disease and 
other disorders.  
 
Lifestyle   
Lifestyle is also thought to have a strong influence on microbiome composition. Cohabitation 
with pets, such as dogs, has a statistically significant association with the microbiome. In one 
study, the skin microbiome of couples living together has a closer resemblance if the couple has 
a dog, but, intriguingly, a small child did not provide the same trend, so couples with a child but 
no dog were not significantly more similar to one another than couples without a child52. Pet 
ownership and exposure to livestock have been associated with decreased risk of asthma53. 
Interrupting this exposure in infants from human populations with a known ancestral history of 
interaction with animals has been shown to lead to a substantial increase in atopy, especially 
asthma54. If these results turn out to be caused by the microbiome, rather than simply correlative, 
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they suggest potential new therapeutic strategies for disease intervention could come from 
microbial exposure focused on immune activation.  
 
Other lifestyle traits have been shown to correlate with the composition of the microbiota. For 
example, exercise appears to influence the structure of the microbiome through reducing 
inflammation, with subtle changes in the microbial community composition correlated with 
changes in cytokine profiles55. Sleep deprivation correlates with changes in the gut microbiome, 
with a greater ratio of Firmicutes to Bacteroidetes and elevated abundance of Coriobacteriaceae 
and Erysipelotrichaceae associated with sleep loss56. Stress increases intestinal permeability, and 
is correlated with changes in Bacteroidetes and Actinobacteria, with corresponding shifts in 
metabolite concentrations and inflammatory markers57.  
 
Occupation has primarily been assumed to influence the microbiome via exposure to different 
environments and place of residence. For example, farmers have a different microbiome than 
city workers58. However, very few microbiome studies have isolated occupation as a variable 
influencing composition. For example, the oral microbiota of sailors is significantly altered by 
their occupational activities, so that after 120 days at sea, they show a five-fold reduction in 
alpha diversity and an increase Streptococcus59. Similarly, sexual intercourse in heterosexual 
couples leads to an increased similarity of the penile and vaginal microbiota between sexual 
partners, which could potentially alter sexual disease ecology in the participants;  there is 
emerging evidence that microbiome differences might affect transmission of STIs (Sexually 
Transmitted Infections)60. Finally, couples who physically interact have a more similar 
microbiota than people who share the same living quarters but do not physically interact14, 
indicating that physical interaction influence microbial sharing and hence microbiome similarity,  
highlighting the effects of social interaction on the microbiome. 
 
Dynamics of the human microbiome  
 
Human interaction with the environment, including with other people, creates the potential for 
specific microbial taxa to either act as an immune-stimulant that influences the microbiome 
through, for example, inflammation, or to act as a source for bacteria, fungi, and viruses that can 
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colonize the human body. The identification of bacterial taxa in the gut that alter animal 
hormonal regulation, leading to obesity in mice61, suggests that such events may alter our 
physiology. The composition of the gut microbiome itself is influenced by circadian rhythm, and 
which also then affect host circadian cycles (Figure 2). Disruption of the microbial diurnal cycle 
can lead to disruption in host circadian rhythms, which can specifically alter hormone regulation 
in mice 62. The human microbiome demonstrates enormous plasticity, while also being extremely 
robust on longer timescales and to larger types of variation31,34,35, but experiments in mouse 
models have shown some of the ways in which it can be re-shaped. 
 
This apparent dichotomy between dynamism and robustness of the microbiome at first glance 
seems difficult to resolve, until the ecological dynamics of the system are considered. All 
ecosystems undergo variation in species population density and assemblage diversity, but with 
differing magnitudes at different temporal scales. This variation includes competition among 
microbial taxa and shifting metabolic relationships, compounded and influenced by the state of 
the immune system, changing dietary patterns, and a constant exposure to bacteria from family 
and environment. Longitudinal characterization of the host microbiome and its sources is 
therefore essential to capture dynamic variance within an individual, and to determine the degree 
to which the system demonstrates predictable successional traits63. 
  
The plasticity vs. stability dichotomy of the human microbiome is evident over a period of days, 
as was illustrated in the first dense time series analysis of the human microbiome 31 and 
confirmed in later ones 34. In that study, two subjects provided daily samples of their oral, skin 
and faecal microbiota, one for six months and the other for fifteen months. The results illustrated 
that at the sequencing depth studied only a tiny fraction of bacterial taxa were found to be 
consistently present across all (or even most) samples in an individual host. For the skin sites 
(the left and right palm) there were no species detected in all samples, while in the gut and the 
mouth, about 5% of the species were defined as belonging to a stable temporal core microbiome. 
Yet each person still maintained a personalized microbiome. The degree of personalization of the 
human microbiome vastly exceeds the host genome, which is over 99.5% identical between 
individuals, suggesting that only 0.5% of the genome is unique to an individual. However, based 
on current observations, two individuals can show no overlap in microbial species in their 
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microbiome. This degree of personalization is so high that it may even have forensic 
applications64.  
  
While we are now used to thinking about the composition of the human microbiome being 
personalized, it has also been shown that the rate of change of the human microbiome 
composition is personalized65. In that study, over an approximately three-month period, 85 
college age adults donated weekly microbiome samples from gut, skin, and oral sites. Over this 
timeframe, the microbiome composition remained almost constant in some individuals, while 
that in other individuals abundances changed rapidly. These differing rates of temporal 
variability were identified at all of the body sites that were profiled (the palm of the dominant 
hand, the forehead, the tongue, and faeces), and the rate of change was not correlated across the 
different sites. On average, skin sites changed most rapidly, followed by the gut, and then oral 
(this pattern matches the relative sizes of the stable temporal core microbiome observed in the 
long-term survey mentioned above31). One potential reason for the dynamics in skin is that there 
are many species at low abundance. None of the information collected about the host correlated 
with the differing rates of change in the microbiome, so it was not possible to determine the 
underlying cause of these differences. However, one interesting observation was that individuals 
who self-reported taking antibiotics during (or in the week preceding) the sampling period did 
not change their microbiome composition more rapidly than subjects who did not report taking 
antibiotics. The absence of a difference may reflect that a one-week time frame does not fully 
capture the effects of recent or even lifetime antibiotic use. Nevertheless, on a per individual 
basis, in this study, reported antibiotic usage was typically associated with the largest change in 
an individual’s microbiome overall.  
  
While most studies associate microbiome composition with host disease state, and likelihood of 
response to a treatment, at least one recent study suggests that the rate of change of the 
microbiome may itself be a clinical feature66, as also was observed in a mouse model of juvenile 
diabetes 67. The rate of change of the vaginal microbiome differed across women with bacterial 
vaginosis, and was predictive of the subtype of bacterial vaginosis affecting the women. That 
observation, paired with data indicating that individuals differ in the rate of change of their gut, 
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skin, and oral microbiomes, suggests that characterizing temporal variability may be an 
important part of characterizing an individual’s microbiome. 
 
Understanding traits such as variance in microbiome dynamics in individuals, and whether that 
relates to  patterns of succession will simplify understanding of causal relationships between 
species and disease, and the interpretation of correlations among  taxonomic groups68. By 
prospectively assessing the microbiomes of patients undergoing different procedures, we can 
determine the rate of change, and potentially the rate of recovery of the microbiome, if it is 
altered by the procedure or by the disease state that led to the procedure. Doing this in a human 
population will provide the statistical power to relate these measurements to remission of clinical 
symptoms. Examining the sources that shape the microbiome is key to determining this variance.  
 
Bayesian statistics can also be used to map the relative contribution of a specific source to the 
human microbiome over time69, or to create artificial neural networks of conditional 
dependencies that can be used to capture predictive characteristics of a microbial network70,71. 
Using these methods, the dynamic nature of the human microbiome or metabolome both within 
an individual and within a population of individuals can be captured. Once gathered, the data can 
be harnessed to provide a predictive signature or characteristic biomarker for a given 
physiological, immunological or neurological condition. The application of machine learning 
algorithms have also proven to be valuable in identifying highly predictive characteristics of a 
microbial signature to map forensic relationships between humans and their built environments14. 
 
 
Towards Mechanistic Studies of the Microbiome 
 
Mechanistic studies of the microbiome are typically difficult to perform in humans, in part 
because of tremendous genetic and lifestyle heterogeneity, and there are ethical issues associated 
with colonizing human subjects with microbes that are hypothesized to cause disease. Therefore, 
most of what we know currently stems from experiments in animal models. However, recent 
studies that complement observations in humans with interventions in animal models have 
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produced striking new insight into the microbial origins of disease that cannot be acquired from 
human studies alone. 
 
The importance of strain-level resolution for microbiome studies 
 
The field of host-pathogen interactions has long relied on culturing strains of pathogens 
including clinical isolates, and transferring these pathogens to isolated cells, tissues, or whole 
animals to perform intervention studies. Many components of the microbiome have been 
inaccessible to such techniques because the relevant organisms cannot be cultured, although 
recent advances greatly expand the repertoire of the organisms that can be grown from the 
human gut72 so this barrier may be temporary. However, the culturable component of the 
microbiome can still be extraordinarily useful, even if incomplete. For example, a recent study in 
which 53 strains of bacteria were isolated from the human gut and used to monocolonize 
previously germ-free mice revealed large differences in immunomodulatory properties of these 
bacteria, including closely related strains that affected production of cytokines such as IL10, 
IL17a, IL22, and interferon gamma with some promoting and others inhibiting production73. 
These results underscore the need to characterize microbial activity at the strain level, not just at 
the higher taxonomic levels that are typically provided by amplicon profiling, and will probably 
reveal important links between the microbiome and disease when extended to more complex 
communities.  
 
Identifying disease - relevant strains from population studies 
 
Population-based microbiome studies complemented with mechanistic experimental work in 
mice can use microbial associations with phenotype in humans to identify bacteria or compounds 
that then can be tested in intervention studies to reveal causal pathways. For example, a study of 
heritability of different taxa within the gut microbiome in twins in the UK revealed that one 
specific taxon, Christensenella, was highly heritable and associated with low BMI in this 
population15. Strains from this genus were cultured in the lab, and then transplanted into germ-
free mice, resulting in decreased weight gain in these mice when compared to transplantation 
from an obese human, which would normally induce weight gain (as described above).  
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Similarly, in a comparative study of different human populations in Finland, Russia and Estonia, 
which differ dramatically in the incidence of early-onset autoimmune diseases, Bacteroides sp. 
were especially common in the gut microbiomes of Finnish and Estonian children, in whom the 
incidence of the diseases were lowest, and were hypothesized to provide most of the LPS 
(lipopolysaccharide; a common marker of bacterial infection in the bloodstream) exposure in 
those populations. In contrast, the Russian children had high levels of E. coli. in their 
microbiomes. Tests of the effect injections of LPS from E. coli and B. dorei showed that the 
former, but not the latter, protected mice with a genetic defect from developing autoantibodies 
and diabetes symptoms, providing a potential explanation for the consequences of the different 
early-life microbiomes on development of autoimmune disease in humans74. A similar strategy 
was used to explain differences in asthma development between Amish and Hutterite children in 
the United States.  Dust extracts from houses from each population,  shown to differ in their 
microbiome content, were tested in a mouse model of asthma development that examines 
sensitivity to ovalbumin. The tests indicated that the dust from Amish but not Hutterite homes 
protected against asthma development54, which was attributed to differences in the bacterial 
content of the dust. These strategies are broadly applicable to many other situations in which 
differential exposure to environmental bacteria may play a role in disease etiology. 
 
Identifying biomarkers in microbiome studies 
 
Some studies are now performing these types of mechanistic experiments in humans directly. In 
one striking example, examining 500 European-ancestry individuals in the Netherlands, the 
authors tested the ability of the individual’s blood to produce cytokines after several antigen 
challenges, then paired these with data about their gut metagenome. The data suggest that the 
yeast Candida albicans had an especially large influence on the host’s TNF-alpha response21. 
This study also associated  pathways active in bacteria such as palmitoleic acid metabolism with 
lower systemic inflammatory response; adding palmitoleic acid in challenge with C. albicans to 
an individual’s blood resulted in lower TNF-alpha, but unchanged IFN-gamma responses, as 
predicted from the association data. These types of studies are especially useful in conjunction 
with humans with naturally occurring genetic knockouts or variant alleles. These human genetic 
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variants may enable microbially induced disease states that can be tested in mice with 
comparable null or variant genetic changes, as has been shown for Parkinson’s Disease.73 
 
Characterizing microbial biomarkers has great potential for precision medicine, and is 
therefore a relatively simple way of translating microbiome research into clinical practice. For 
example, from groundbreaking animal studies, we know that bacterial probiotics (live bacteria 
deliberately introduced to the animal to produce a therapeutic effect) can be used to enhance 
immune checkpoint blockade therapy for melanoma patients75. Studying the microbiomes of 
melanoma patients prior to immune checkpoint blockade therapy has identified 
microorganisms in the gut to be biomarkers for diagnosis that can predict whether patients are 
at risk of developing checkpoint-blockade-induced colitis76.  
 
These prospective studies are extremely important for linking microbial community structure, 
function, and metabolic products to health outcomes. Studies of the microbiome as infants 
develop are also key in this area, and many ongoing investigations, such as the NIH Common 
Core program Environmental Influences on Child Health Outcomes (ECHO: 
https://www.nih.gov/echo), now provide the infrastructure to sequence healthy, susceptible 
and diseased participants to examine how lifestyle and environmental experiences shape the 
development of immune, endocrine and neurological conditions. Although cross-sectional 
single time point studies of birth cohorts provide intriguing statistical associations77, 
longitudinal prospective studies complemented by mechanistic experiments in animal models 
are required to establish whether a certain microbiome causes disease.  
 
Future studies: developing translational potential 
 
There remains much that we do not understand about the human microbiome. The sources of 
bacteria that colonize an infant include the mother and other caregivers (even one-day-old pre-
term infants have unique microbiomes that differ from each other and from the mother but 
possibly derived from their mothers78), and human genetics shapes microbiome-immune 
interaction. Given these observations, why do monozygotic twins growing up in the same 
household develop microbiomes that are barely more similar than those of dizygotic twins? The 
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role of exogenous immune stimulation in shaping the colonization efficiency of different strains 
must be investigated in more detail. Animal models have produced intriguing findings, but 
prospective longitudinal studies in human infants are required to better understand how human 
genetics influence the developing microbiome. These longitudinal investigations will also help 
us to understand the implication of ecological dynamics of the microbiome in health and disease. 
Microbiome stability (resistance to change) and resilience (return to the initial state following 
perturbation) are essential but poorly understood ecological characteristics that can be quantified 
through longitudinal studies by serial collection of DNA sequence data from the microbiome, 
perhaps complemented by metabolite and gene expression profiling. For example, performing 
weekly microbiome profiling of participants before, during. and after surgery could help  identify 
whether (and which) microbiome ecological dynamics are linked to response to surgery, 
complications, and recovery. Similarly, understanding the resistance and resilience of the 
microbiome to antibiotics requires larger-scale longitudinal studies of diverse cohorts (Figure 3). 
This is especially relevant in childhood, when the microbiome is in flux and may be less 
resistant, but more resilient to these stresses.  
 
As we move forward with transforming microbiome research from a descriptive to causal, and 
finally translational science, the ability to define biomarkers that can stratify patient populations 
within a disease state represents ‘low-hanging fruit’ (Box 2). Of course, the effort required to 
take advantage of these biomarkers is considerable. Clinical studies that recruit large and 
representative patient populations to examine the response to a new drug or therapeutic 
intervention should definitely consider the opportunity to collect data on both immune function 
and the microbiome. These additional variables may lead to new non-invasive diagnostic 
platforms. In the future, it may be possible to request a stool or vaginal sample, or even an saliva 
sample (which has been shown to yield effective microbial biomarkers for diseases not centered 
on the mouth such as rheumatoid arthritis79 (Box 2)) from a patient prior to a surgical 
intervention. Then, along with their genome and medical history, scientists could make a more 
accurate prediction about the likelihood of successful outcome and/or of complications for each 
proposed intervention. This additional information, if presented in a sufficiently clear format, 
would substantially aid clinicians by providing new data layers that enrich the decision-making 
process. To realize this vision, we must better understand the factors that influence the 
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microbiome of a healthy individual, and how the microbiome is reshaped during different health 
and disease states. 
 
Concluding Remarks 
Microbiome analysis, and so-called Microbiome Wide Association Studies (MWAS)10, are 
revolutionizing clinical investigations by providing greater patient stratification and new 
biomarkers of disease. We are poised to make great advances in patient care over the next decade 
as we improve our ability to characterize and manipulate the microbiome and its metabolism. 
The omics tools available to perform this characterization have been developed independently, 
but now there is an ongoing concerted effort80,81 to better standardize and integrate methods and 
data resources to improve our ability to understand microbial dynamics in human systems. 
Systems microbiome medicine approaches are rapidly finding their way into clinical 
investigations, and this is producing a need to integrate traditional clinical statistics and 
epidemiology with microbial ecological statistics and theory. While these two concepts are not 
mutually exclusive, they are often treated as such; a new breed of data scientist is required as 
early-career clinician-scientists develop their new skills in this rapidly expanding field. This in 
turn increases the likelihood that patient cohort studies will be integrated with animal 
investigations that enable more accurate interpretation of observed host-microbiome traits.  
 
It is a brave new world, where ecologists and data scientists are being integrated into clinical 
departments, but this paradigm shift is a necessary precondition to realize the potential of 
microbiome-informed and microbiome-based medicine. The societal need for improved medical 
interventions and preventive strategies is driving a sea-change in both the clinical and 
commercial world. The onus is on the basic and clinical translational research community to 
ensure that our experimental designs are robust and can deliver on the promises of this field. Just 
as important are the technical advances that must occur to ensure that we have the tools to derive 
the data to test our hypotheses. The microbial ecology community came together in 2015-2016 to 
support the proposal for a National Microbiome Initiative, which was in turn supported by the 
United States President’s Office of Science and Technology Policy82; one of the key outcomes of 
this effort was the identification of gaps in our technologies that would need to be filled to 
realize the full potential of microbiome science83. We have a long way to go, but with each new 
  16 
investigation we are moving closer to the realization of more effective diagnosis, treatment, and 
preventive modalities to improve human wellness and fight disease.  
 
Box 1: How many microbial cells and genes colonize a human? 
 Although a frequently reported figure is that our microbes outnumber our own cells by 10:1, this 
number stems from a 1972 article which uses a ‘back of the envelope calculation’ to arrive at this 
ratio84. A more prosaic figure was provided by Rosner85 of between 5 and 724 x 1012 human 
cells, and between 30 and 400 x 1012 bacterial cells. More recently, a refined estimate based on 
experimental observation and extrapolation actually arrives at a ratio of 1.3 bacterial cells for 
every one human cell1. However, these estimates don’t take into consideration the viruses and 
phage present in various body environments, which could equal bacterial estimates or more 
likely outnumber them by at least an order of magnitude86.  Although these estimates reduce the 
extent to which microbial cells outnumber human cells, they do not reduce the estimates 
associated with the diversity of microbial life associated with the human body. Bacteria and 
other microbes including archaea, fungi, and, arguably, viruses, are extremely diverse. A 
similarly rough estimate of 1000 bacterial species in the gut with 2000 genes per species yields 
an estimate of 2,000,000 genes, 100 times the figure of approximately 20,000 human genes2. 
This agrees well with the actual size of microbial gene catalogues obtained by MetaHIT87 and 
the Human Microbiome Project13. 
 
Box 2: The microbiome as novel biomarkers for disease 
There is extensive evidence for many diseases that the microbiome can be used to explain a 
substantially greater percentage of the variance in the relevant phenotypes for a given condition 
within a population than can human genetic factors. For example, in individuals with 
Clostridium difficile infection (CDI), the aberrant stool microbiome looks nothing like a healthy 
stool but rather more like the microbiome of a completely different body site. Fecal microbiota 
transplant is able to cure C. diff infection and after transplantation  the restoration of the stool 
microbiome to a community that matches that of  the healthy state is both rapid and visible88. 
The C. diff infection has a much larger impact on the stool microbiome composition than does 
any human genetic variation observed to date, which may explain the high efficacy of stool 
transplant relative to standard antibiotic treatments for C. diff89.  
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Obesity provides an example in which human genetics has failed to explain the obesity 
epidemic, in contrast, the gut microbiome can classify individuals as lean or obese with over 
90% accuracy within the context of a given case-control study90, although this result depends on 
using the correct methods91,92. Conversely the abundance of Christensenella within the human 
gut are negatively correlated with BMI, and can induce weight loss when experimentally fed to 
mice15.  
 Autism Spectrum Disorder has a complex presentation of symptoms, and is difficult to 
attribute entirely to host genetics, mainly due to the number of confounding influences and 
variables93. Yet the environmental interaction, and potentially the microbiome, plays a 
substantial role in shaping the etiology of the disease94,95. Animal models have been used to 
indicate the ability of bacterial metabolites in mediating autism-like behaviours96, and fecal 
microbiota transplant in humans has been associated with improvement in behavioral and 
gastrointestinal symptoms of autism 97. In further work, the link between host genetics, behavior 
and the gut microbiome has been partially elucidated, identifying a strong association between 
Lactobacillus and memory formation98.   
 A host of allergic and immune diseases has increased in frequency in parallel to the 
above metabolic and cognitive diseases. These include childhood-onset asthma, and allergies, 
including food and cutaneous allergies. Similarly, inflammatory bowel disease and type 1 
diabetes has been increasing globally, which cannot be explained by differences in assessment 
practices. A growing body of evidence is linking these with altered microbiota compositions, 
especially loss of diversity, seen in Inflammatory Bowel Disease patients99,100 and children at 
risk for T1D101.  One hypothesis is that this might be linked to a microbiome perturbation, in 
general, rather than the acquisition or loss of specific microbes that modify phenotype 102. 
Perturbation of microbiomes during early life might be particularly important because that is 
when immunity, metabolism, and cognition are under development. A large Canadian study of 
infant stool samples (n=319) collected over the first 90 days of life, compared the early-life (first 
90 days) faecal microbiota of infants who went on to develop allergic sensitization and wheezing 
at age two, to subjects who did not. The depletion of certain bacterial taxa was characteristic of 
atopic children, and corresponded with reduced concentrations of faecal acetate and 
dysregulation of enterohepatic metabolites103, suggesting that the foundation for allergic disease 
development occurs in early life and is mediated at least in part by gut microbiome dysbiosis.  
  18 
 
Acknowledgements 
Many of the studies described here in our laboratories were supported by the NIH, NSF, DOE, 
and the Alfred P. Sloan Foundation. We thank numerous members of our laboratories for 
constructive criticism on drafts of this article. 
 
References 
1. Sender, R., Fuchs, S. & Milo, R. Are We Really Vastly Outnumbered? Revisiting the Ratio of 
Bacterial to Host Cells in Humans. Cell 164, 337–340 (2016). 
2. Turnbaugh, P. J. et al. The human microbiome project. Nature 449, 804–810 (2007). 
3. Locey, K. J. & Lennon, J. T. Scaling laws predict global microbial diversity. Proc. Natl. Acad. 
Sci. U. S. A. 113, 5970–5975 (2016). 
4. Frank, D. N. et al. Molecular-phylogenetic characterization of microbial community 
imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. U. S. A. 104, 
13780–13785 (2007). 
5. Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host 
Microbe 15, 382–392 (2014). 
6. Ni, J. et al. A role for bacterial urease in gut dysbiosis and Crohn’s disease. Sci. Transl. Med. 
9, (2017). 
7. Kostic, A. D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and 
modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207–215 (2013). 
8. Jiang, H. et al. Altered fecal microbiota composition in patients with major depressive 
disorder. Brain. Behav. Immun. 48, 186–194 (2015). 
9. Zheng, P. et al. Gut microbiome remodeling induces depressive-like behaviors through a 
pathway mediated by the host’s metabolism. Mol. Psychiatry 21, 786–796 (2016). 
10. Gilbert, J. A. et al. Microbiome-wide association studies link dynamic microbial consortia 
to disease. Nature 535, 94–103 (2016). 
  19 
11. Punt, C. J. A., Koopman, M. & Vermeulen, L. From tumour heterogeneity to advances in 
precision treatment of colorectal cancer. Nat. Rev. Clin. Oncol. 14, 235–246 (2017). 
12. Debelius, J. et al. Tiny microbes, enormous impacts: what matters in gut microbiome 
studies? Genome Biol. 17, 217 (2016). 
13. Integrative HMP (iHMP) Research Network Consortium. The Integrative Human 
Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of 
human health and disease. Cell Host Microbe 16, 276–289 (2014). 
14. Lax, S. et al. Longitudinal analysis of microbial interaction between humans and the 
indoor environment. Science 345, 1048–1052 (2014). 
15. Goodrich, J. K. et al. Human Genetics Shape the Gut Microbiome. Cell 159, 789–799 
(2014). 
16. Ridaura, V. K. et al. Gut microbiota from twins discordant for obesity modulate 
metabolism in mice. Science 341, 1241214 (2013). 
17. Turnbaugh, P. J. et al. Organismal, genetic, and transcriptional variation in the deeply 
sequenced gut microbiomes of identical twins. Proc. Natl. Acad. Sci. U. S. A. 107, 7503–
7508 (2010). 
18. Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480–
484 (2009). 
19. Seedorf, H. et al. Bacteria from diverse habitats colonize and compete in the mouse gut. 
Cell 159, 253–266 (2014). 
20. Karczewski, J., Poniedziałek, B., Adamski, Z. & Rzymski, P. The effects of the 
microbiota on the host immune system. Autoimmunity 47, 494–504 (2014). 
21. Schirmer, M. et al. Linking the Human Gut Microbiome to Inflammatory Cytokine 
Production Capacity. Cell 167, 1897 (2016). 
22. Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K. & Knight, R. Diversity, 
stability and resilience of the human gut microbiota. Nature 489, 220–230 (2012). 
  20 
23. O’Toole, P. W. Changes in the intestinal microbiota from adulthood through to old age. 
Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 18 Suppl 4, 44–46 
(2012). 
24. Koenig, J. E. et al. Succession of microbial consortia in the developing infant gut 
microbiome. Proc. Natl. Acad. Sci. U. S. A. 108 Suppl 1, 4578–4585 (2011). 
25. Weng, M. & Walker, W. A. The role of gut microbiota in programming the immune 
phenotype. J. Dev. Orig. Health Dis. 4, 203–214 (2013). 
26. Maynard, C. L., Elson, C. O., Hatton, R. D. & Weaver, C. T. Reciprocal interactions of 
the intestinal microbiota and immune system. Nature 489, 231–241 (2012). 
27. Knights, D. et al. Rethinking ‘enterotypes’. Cell Host Microbe 16, 433–437 (2014). 
28. Jeffery, I. B., Claesson, M. J., O’Toole, P. W. & Shanahan, F. Categorization of the gut 
microbiota: enterotypes or gradients? Nat. Rev. Microbiol. 10, 591–592 (2012). 
29. Grice, E. A. & Segre, J. A. The skin microbiome. Nat. Rev. Microbiol. 9, 244–253 (2011). 
30. Grice, E. A. et al. Topographical and temporal diversity of the human skin microbiome. 
Science 324, 1190–1192 (2009). 
31. Caporaso, J. G. et al. Moving pictures of the human microbiome. Genome Biol. 12, R50 
(2011). 
32. Kort, R. et al. Shaping the oral microbiota through intimate kissing. Microbiome 2, 41 
(2014). 
33. Lazarevic, V., Whiteson, K., Hernandez, D., François, P. & Schrenzel, J. Study of inter- 
and intra-individual variations in the salivary microbiota. BMC Genomics 11, 523 (2010). 
34. David, L. A. et al. Host lifestyle affects human microbiota on daily timescales. Genome 
Biol. 15, R89 (2014). 
35. David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 
505, 559–563 (2014). 
  21 
36. Maier, T. V. et al. Impact of Dietary Resistant Starch on the Human Gut Microbiome, 
Metaproteome, and Metabolome. mBio 8, e01343-17 (2017). 
37. Hannigan, G. D. et al. The human skin double-stranded DNA virome: topographical and 
temporal diversity, genetic enrichment, and dynamic associations with the host microbiome. 
mBio 6, e01578-01515 (2015). 
38. Vandeputte, D. et al. Quantitative microbiome profiling links gut community variation to 
microbial load. Nature 551, 507–511 (2017). 
39. Vandeputte, D. et al. Stool consistency is strongly associated with gut microbiota 
richness and composition, enterotypes and bacterial growth rates. Gut 65, 57–62 (2016). 
40. Ma, B., Forney, L. J. & Ravel, J. Vaginal microbiome: rethinking health and disease. 
Annu. Rev. Microbiol. 66, 371–389 (2012). 
41. Ravel, J. et al. Daily temporal dynamics of vaginal microbiota before, during and after 
episodes of bacterial vaginosis. Microbiome 1, 29 (2013). 
42. Romero, R. et al. The composition and stability of the vaginal microbiota of normal 
pregnant women is different from that of non-pregnant women. Microbiome 2, 4 (2014). 
43. Xiao, B. et al. Predictive value of the composition of the vaginal microbiota in bacterial 
vaginosis, a dynamic study to identify recurrence-related flora. Sci. Rep. 6, 26674 (2016). 
44. Albenberg, L. G. & Wu, G. D. Diet and the intestinal microbiome: associations, functions, 
and implications for health and disease. Gastroenterology 146, 1564–1572 (2014). 
45. Wu, G. D. et al. Linking long-term dietary patterns with gut microbial enterotypes. 
Science 334, 105–108 (2011). 
46. Zeevi, D. et al. Personalized Nutrition by Prediction of Glycemic Responses. Cell 163, 
1079–1094 (2015). 
47. Zhang, C. et al. Dietary Modulation of Gut Microbiota Contributes to Alleviation of Both 
Genetic and Simple Obesity in Children. EBioMedicine 2, 968–984 (2015). 
  22 
48. Modi, S. R., Collins, J. J. & Relman, D. A. Antibiotics and the gut microbiota. J. Clin. 
Invest. 124, 4212–4218 (2014). 
49. Dethlefsen, L. & Relman, D. A. Incomplete recovery and individualized responses of the 
human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl. Acad. Sci. U. S. A. 
108 Suppl 1, 4554–4561 (2011). 
50. Maurice, C. F., Haiser, H. J. & Turnbaugh, P. J. Xenobiotics shape the physiology and 
gene expression of the active human gut microbiome. Cell 152, 39–50 (2013). 
51. Trasande, L. et al. Infant antibiotic exposures and early-life body mass. Int. J. Obes. 
2005 37, 16–23 (2013). 
52. Song, S. J. et al. Cohabiting family members share microbiota with one another and with 
their dogs. eLife 2, e00458 (2013). 
53. von Mutius, E. The microbial environment and its influence on asthma prevention in 
early life. J. Allergy Clin. Immunol. 137, 680–689 (2016). 
54. Stein, M. M. et al. Innate Immunity and Asthma Risk in Amish and Hutterite Farm 
Children. N. Engl. J. Med. 375, 411–421 (2016). 
55. Cook, M. D. et al. Exercise and gut immune function: evidence of alterations in colon 
immune cell homeostasis and microbiome characteristics with exercise training. Immunol. 
Cell Biol. 94, 158–163 (2016). 
56. Benedict, C. et al. Gut microbiota and glucometabolic alterations in response to 
recurrent partial sleep deprivation in normal-weight young individuals. Mol. Metab. 5, 1175–
1186 (2016). 
57. Karl, J. P. et al. Changes in intestinal microbiota composition and metabolism coincide 
with increased intestinal permeability in young adults under prolonged physiological stress. 
Am. J. Physiol. Gastrointest. Liver Physiol. 312, G559–G571 (2017). 
58. Ying, S. et al. The Influence of Age and Gender on Skin-Associated Microbial 
Communities in Urban and Rural Human Populations. PloS One 10, e0141842 (2015). 
  23 
59. Zheng, W. et al. Metagenomic sequencing reveals altered metabolic pathways in the 
oral microbiota of sailors during a long sea voyage. Sci. Rep. 5, 9131 (2015). 
60. Zozaya, M. et al. Bacterial communities in penile skin, male urethra, and vaginas of 
heterosexual couples with and without bacterial vaginosis. Microbiome 4, (2016). 
61. Fei, N. & Zhao, L. An opportunistic pathogen isolated from the gut of an obese human 
causes obesity in germfree mice. ISME J. 7, 880–884 (2013). 
62. Leone, V. et al. Effects of Diurnal Variation of Gut Microbes and High-Fat Feeding on 
Host Circadian Clock Function and Metabolism. Cell Host Microbe 17, 681–689 (2015). 
63. Knight, R. et al. Unlocking the potential of metagenomics through replicated 
experimental design. Nat. Biotechnol. 30, 513–520 (2012). 
64. Fierer, N. et al. Forensic identification using skin bacterial communities. Proc. Natl. 
Acad. Sci. U. S. A. 107, 6477–6481 (2010). 
65. Flores, G. E. et al. Temporal variability is a personalized feature of the human 
microbiome. Genome Biol. 15, 531 (2014). 
66. Gajer, P. et al. Temporal dynamics of the human vaginal microbiota. Sci. Transl. Med. 4, 
132ra52 (2012). 
67. Livanos, A. E. et al. Antibiotic-mediated gut microbiome perturbation accelerates 
development of type 1 diabetes in mice. Nat. Microbiol. 1, 16140 (2016). 
68. Sugihara, G. et al. Detecting Causality in Complex Ecosystems. Science 338, 496–500 
(2012). 
69. Knights, D. et al. Bayesian community-wide culture-independent microbial source 
tracking. Nat. Methods 8, 761–763 (2011). 
70. Larsen, P. E., Field, D. & Gilbert, J. A. Predicting bacterial community assemblages 
using an artificial neural network approach. Nat. Methods 9, 621–625 (2012). 
71. Larsen, P. E. & Dai, Y. Metabolome of human gut microbiome is predictive of host 
dysbiosis. GigaScience 4, 42 (2015). 
  24 
72. Browne, H. P. et al. Culturing of ‘unculturable’ human microbiota reveals novel taxa and 
extensive sporulation. Nature 533, 543–546 (2016). 
73. Geva-Zatorsky, N. et al. Mining the Human Gut Microbiota for Immunomodulatory 
Organisms. Cell 168, 928–943.e11 (2017). 
74. Vatanen, T. et al. Variation in Microbiome LPS Immunogenicity Contributes to 
Autoimmunity in Humans. Cell 165, 842–853 (2016). 
75. Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates 
anti-PD-L1 efficacy. Science 350, 1084–1089 (2015). 
76. Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for 
checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016). 
77. Mueller, N. T. et al. Does vaginal delivery mitigate or strengthen the intergenerational 
association of overweight and obesity? Findings from the Boston Birth Cohort. Int. J. Obes. 
2005 41, 497–501 (2017). 
78. Raveh-Sadka, T. et al. Gut bacteria are rarely shared by co-hospitalized premature 
infants, regardless of necrotizing enterocolitis development. eLife 4, (2015). 
79. Zhang, X. et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and 
partly normalized after treatment. Nat. Med. 21, 895–905 (2015). 
80. Sinha, R. et al. Assessment of variation in microbial community amplicon sequencing by 
the Microbiome Quality Control (MBQC) project consortium. Nat. Biotechnol. 35, 1077–1086 
(2017). 
81. Costea, P. I. et al. Towards standards for human fecal sample processing in 
metagenomic studies. Nat. Biotechnol. 35, 1069–1076 (2017). 
82. Alivisatos, A. P. et al. A unified initiative to harness Earth’s microbiomes. Science 350, 
507–508 (2015). 
83. Biteen, J. S. et al. Tools for the Microbiome: Nano and Beyond. ACS Nano 10, 6–37 
(2016). 
  25 
84. Luckey, T. D. Introduction to intestinal microecology. Am. J. Clin. Nutr. 25, 1292–1294 
(1972). 
85. Rosner, J. L. Ten Times More Microbial Cells than Body Cells in Humans? Microbe Mag. 
9, 47–47 (2014). 
86. Reyes, A. et al. Viruses in the faecal microbiota of monozygotic twins and their mothers. 
Nature 466, 334–338 (2010). 
87. Qin, J. et al. A human gut microbial gene catalogue established by metagenomic 
sequencing. Nature 464, 59–65 (2010). 
88. Weingarden, A. et al. Dynamic changes in short- and long-term bacterial composition 
following fecal microbiota transplantation for recurrent Clostridium difficile infection. 
Microbiome 3, 10 (2015). 
89. Kassam, Z., Lee, C. H., Yuan, Y. & Hunt, R. H. Fecal microbiota transplantation for 
Clostridium difficile infection: systematic review and meta-analysis. Am. J. Gastroenterol. 
108, 500–508 (2013). 
90. Knights, D., Parfrey, L. W., Zaneveld, J., Lozupone, C. & Knight, R. Human-associated 
microbial signatures: examining their predictive value. Cell Host Microbe 10, 292–296 (2011). 
91. Walters, W. A., Xu, Z. & Knight, R. Meta-analyses of human gut microbes associated 
with obesity and IBD. FEBS Lett. 588, 4223–4233 (2014). 
92. Sze, M. A. & Schloss, P. D. Looking for a Signal in the Noise: Revisiting Obesity and the 
Microbiome. mBio 7, (2016). 
93. Sahin, M. & Sur, M. Genes, circuits, and precision therapies for autism and related 
neurodevelopmental disorders. Science 350, (2015). 
94. McDonald, D. et al. Towards large-cohort comparative studies to define the factors 
influencing the gut microbial community structure of ASD patients. Microb. Ecol. Health Dis. 
26, 26555 (2015). 
  26 
95. Kang, D.-W. et al. Reduced Incidence of Prevotella and Other Fermenters in Intestinal 
Microflora of Autistic Children. PLoS ONE 8, e68322 (2013). 
96. Hsiao, E. Y. et al. Microbiota Modulate Behavioral and Physiological Abnormalities 
Associated with Neurodevelopmental Disorders. Cell 155, 1451–1463 (2013). 
97. Kang, D.-W. et al. Microbiota Transfer Therapy alters gut ecosystem and improves 
gastrointestinal and autism symptoms: an open-label study. Microbiome 5, 10 (2017). 
98. Snijders, A. M. et al. Influence of early life exposure, host genetics and diet on the 
mouse gut microbiome and metabolome. Nat. Microbiol. 2, 16221 (2016). 
99. Knights, D. et al. Complex host genetics influence the microbiome in inflammatory bowel 
disease. Genome Med. 6, 107 (2014). 
100. Halfvarson, J. et al. Dynamics of the human gut microbiome in inflammatory bowel 
disease. Nat. Microbiol. 2, 17004 (2017). 
101. Uusitalo, U. et al. Association of Early Exposure of Probiotics and Islet Autoimmunity in 
the TEDDY Study. JAMA Pediatr. 170, 20–28 (2016). 
102. Blaser, M. J. The theory of disappearing microbiota and the epidemics of chronic 
diseases. Nat. Rev. Immunol. 17, 461–463 (2017). 
103. Arrieta, M.-C. et al. Early infancy microbial and metabolic alterations affect risk of 
childhood asthma. Sci. Transl. Med. 7, 307ra152 (2015). 
 
